Doxepin hydrochloride

DUBLIN--(BUSINESS WIRE)--The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the Insomnia market through 2032. Z-drugs are the most common first-line treatment for insomnia across the US and 5EU. The insomnia pipeline in the 7MM is sparse but varied, containing products with varying mechanisms of action. There are five pipeline products in Phase II and III stages of clinical development for insomnia. The insomnia market across the 7MM was valued at $3.1 billion in the 2022 baseline year. Over the 10- year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching $3.8 billion by 2032. The entry of the two pipeline products during the forecast period will have a significant impact on the market. They are anticipated to contribute $288 million in sales by 2032. Report Scope Reasons to Buy Key Topics Covered: 1. Preface 1.1. Contents 1.2. Abbreviations 1.3. Related Reports 2. Executive Summary 2.1. Summary of Updates 3. Disease Overview 3.1. Overview of Insomnia 3.2. Insomnia SWOT Analysis 3.3. Pathophysiology of Insomnia 3.4. Classification of Insomnia 4. Epidemiology 4.1. Total Prevalent Cases of Insomnia, Both Sexes, Ages 15 Years, 2022-32 4.2. Age-Specific Trends in the Total Prevalent Cases of Insomnia, Both Sexes, 2022 4.3. Sex-Specific Total Prevalent Cases of Insomnia, Both Sexes, Ages 15 Years, 2022 4.4. Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages 15 Years, 2022 4.5. Sex-Specific Total Prevalent Cases of Chronic Insomnia, Ages 15 Years, 2022 4.6. Sources and Methodology for Acute and Chronic Insomnia Prevalence 4.7. Sources and Methodology - Total Prevalent Cases of Acute and Chronic Insomnia 5. Current Treatment Options 5.1. Treatment Paradigm 5.2. Current Treatment Options 5.3. Product Profile: Benzodiazepines (e.g., estazolam, temazepam, flurazepam) 5.4. Product Profile: Z-Drugs (zaleplon, zolpidem, zopiclone, eszopiclone) 5.5. Product Profile: Melatonin Receptor Agonists (ramelteon and melatonin ER) 5.6. Product Profile: Low-Dose Antidepressants (doxepin, trazodone, trimipramine) 5.7. Product Profile: Antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine) 5.8. Product Profile: Gabapentinoids (e.g., gabapentin and pregabalin) 5.9. Product Profile: Merck & Co's Belsomra (suvorexant) 5.10. Product Profile: Eisai's Dayvigo (lemborexant) 5.11. Product Profile: Idorsia's Quviviq (daridorexant) 5.12. Product Profile: Taisho Pharmaceutical's Borzi (vornorexant) 5.13. Patient Flow: Insomnia in 2022 Across 7MM 6. Unmet Needs and Opportunities 6.1. Unmet Needs in Insomnia 6.2. New Therapeutic Options with Improved Efficacy 6.3. Improved Physician Awareness of Insomnia Treatments 6.4. Improved Patient Access to CBT-i 7. R&D Strategies 7.1. Trends in Clinical Trial Design in Insomnia 7.2. Trends in Deal-Making in Insomnia 8. Pipeline Assessment 8.1. Insomnia Pipeline Overview 8.2. Late-Stage Pipeline Agents for Insomnia 8.3. Product Profile: EUSOL Biotech's SM-1 8.4. Product Profile: Imbrium Therapeutics's Sunobinop 8.5. Product Profile: Vanda Pharmaceuticals's Hetlioz (tasimelteon) 8.6. Insomnia: Clinical Trials (Phase II/III) Overview 9. Market Outlook 9.1. Insomnia Market Forecast 9.2. Market Drivers and Barriers 10. Appendix 10.1. Primary Research: KOL Information 10.2. Primary Research: High-Prescriber Survey Information 10.3. Bibliography 10.4. About the Authors Companies Featured For more information about this report visit https://www.researchandmarkets.com/r/dns27p About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

TUESDAY, Oct. 28, 2025 -- Antidepressants induce cardiometabolic and other physiological alterations, which vary between medications, according to a study published online Oct. 21 in The Lancet . Toby Pillinger, Ph.D., from King's College London, and colleagues compared and ranked antidepressants based on physiological side effects using data from randomized controlled trials. A total of 151 studies and 17 U.S. Food and Drug Administration reports met the inclusion criteria. Overall, 58,534 participants were included and 30 antidepressants were compared to placebo. The researchers found that in terms of metabolic and hemodynamic effects, there were clinically significant differences between antidepressants, including an approximate difference of 4 kg in weight change between agomelatine and maprotiline, a difference of more than 21 beats per minute in change in heart rate between fluvoxamine and nortriptyline, and a difference of more than 11 mmHg in systolic blood pressure between nortriptyline and doxepin. Increases in total cholesterol were seen in association with paroxetine , duloxetine , desvenlafaxine , and venlafaxine ; duloxetine was associated with increased glucose concentrations, despite reductions in body weight with all drugs. No strong evidence was found for any antidepressant affecting QTc or concentrations of sodium, potassium, urea, or creatinine to a clinically significant extent. "We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters," the authors write. "Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text